Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Farkasgyepu – page 12

162 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Farkasgyepu at a glance
162
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

162 trials in Farkasgyepu

Open in trial search

Cardiac failure

Not recruiting

Study of XXB750 and Drug Combination for Patients with Heart Failure

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azilsartan Medoxomil
  • Sponsor:Novartis Pharma AG

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Active Psoriatic Arthritis in Patients with Inadequate Response to One Prior Anti-TNF Agent

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Study on Mavacamten for Adults with Non-obstructive Hypertrophic Cardiomyopathy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Mavacamten
  • Sponsor:Myokardia Inc.

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Reduced Ejection Fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Betula Pollen Extract for Children and Adolescents Aged 5-17 with Birch Pollen Allergies and Possible Asthma

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Betula Pollen Extract
  • Sponsor:Stallergenes

Study of Secukinumab for Maintaining Remission in Patients with Non-Radiographic Axial Spondyloarthritis

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Secukinumab
  • Sponsor:Novartis Pharma AG

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine
  • Sponsor:Cardurion Pharmaceuticals Inc.

Study on the Effectiveness of Enlicitide Chloride in Reducing Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Enlicitide decanoate
  • Sponsor:Merck Sharp & Dohme LLC

Psoriasis

Not recruiting

Study on Adjustable Brodalumab Dosage for Patients with Moderate-to-Severe Plaque Psoriasis Weighing 120 kg or More

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Brodalumab
  • Sponsor:Leo Pharma A/S

Study of Immunotherapy Combinations with GSK4428859, Dostarlimab, and GSK6097608 for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Colitis ulcerative

Not recruiting

Long-Term Safety Study of Obefazimod for Patients with Moderate to Severe Ulcerative Colitis

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Cardiac failure

Not recruiting

Study on Balcinrenone and Dapagliflozin for Patients with Heart Failure and Kidney Problems

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Balcinrenone
  • Sponsor:Astrazeneca AB

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Farkasgyepu

What the registry says about research in the country

01 Lung Cancer Immunotherapy

Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.

  • Novel immunotherapy combinations
  • PD-L1 targeted therapies
  • First-line treatment strategies

Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.

02 Advanced NSCLC Treatments

Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.

  • Mutation-specific treatments
  • Combination therapy approaches
  • Novel drug development

Investigations focus on personalized treatment strategies for different NSCLC subtypes.

03 Small Cell Lung Cancer Research

Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.

  • Single-agent therapies
  • Combination treatments
  • Survival outcome studies

Research focuses on improving treatment options for patients with relapsed SCLC.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.